Loading...
•
Mar 31, 2024
Aclaris Therapeutics Q1 2024 Earnings Report
Aclaris Therapeutics reported first quarter 2024 financial results.
Key Takeaways
Aclaris Therapeutics reported a net loss of $16.9 million and total revenue of $2.4 million for the first quarter of 2024. The company is progressing ATI-2138 into a Phase 2a trial for atopic dermatitis and seeking a partner for lepzacitinib. They had cash, cash equivalents, and marketable securities of $161.4 million as of March 31, 2024.
Aclaris plans to progress ATI-2138 into a Phase 2a trial in subjects with moderate to severe atopic dermatitis.
Aclaris is progressing to development candidate selection a second generation ITK selective inhibitor for autoimmune indications.
Aclaris is currently seeking a global development and commercialization partner for Lepzacitinib (excluding Greater China).
Aclaris plans to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris anticipates payments associated with exit activities to be substantially completed by the second quarter of 2024, and expects significantly lower quarterly cash expenditures in future quarters. They are undergoing a strategic review of its business.
Revenue & Expenses
Visualization of income flow from segment revenue to net income